PRESCIENT THERAPEUTICS LIMITED - Announcements

Market Cap $40.26M Add to my watchlist

Healthcare Biotechnology

Prescient Therapeutics Limited is an Australia-based clinical-stage oncology company. The... Prescient Therapeutics Limited is an Australia-based clinical-stage oncology company. The Company is engaged in the development of personalized medicine approaches to cancer, including targeted and cellular therapies. Its product pipeline includes PTX-100, PTX-200, OmniCAR, CellPryme-M and CellPryme-A. PTX-100 is a compound with the ability to block a cancer growth enzyme, geranylgeranyl transferase-1 (GGT-1). PTX-100 is in Phase Ib expansion cohort study in T cell lymphomas. PTX-200 is a PH domain inhibitor that inhibits a tumor survival pathway, Akt. PTX-200 is in Phase Ib/II trial in relapsed and refractory AML. OmniCAR is a universal immune receptor platform enabling controllable T-cell activity and multi-antigen targeting with a single-cell product. CellPryme-M is a platform for enhancing cell therapies by producing cells with superior phenotypes. CellPryme-A is an adjuvant therapy designed to be administered to patients alongside cellular immunotherapy.More

Announcements

Filter Results

All Price Sensitive Only

PTX	March 2024 Quarterly Update and Appendix 4C	PRICE SENSITIVE	30/04/24	392.22KB	Share
PTX	PTX100 Ph1b results to be presented at specialist congress		08/04/24	253.17KB	Share
PTX	Notification of cessation of securities - PTX		05/04/24	12.96KB	Share
PTX	Appendix 4D and Half Year Financial Report	PRICE SENSITIVE	23/02/24	656.43KB	Share
PTX	December 2023 Quarterly Update and Appendix 4C	PRICE SENSITIVE	31/01/24	2.53MB	Share
PTX	PTX-100 Spotlight Presentation		18/12/23	1.35MB	Share
PTX	PTX-100 Ph1b results show excellent safety & efficacy in TCL	PRICE SENSITIVE	11/12/23	1.3MB	Share
PTX	Prescient Receives $2.4 Million R&D Tax Rebate		28/11/23	605.26KB	Share
PTX	Results of Annual General Meeting		16/11/23	468.64KB	Share
PTX	Chair and CEO AGM Presentation		16/11/23	15.43MB	Share
PTX	PTX-100 abstract published online on ASH website		06/11/23	607.01KB	Share
PTX	September 2023 Quarterly Update and Appendix 4C	PRICE SENSITIVE	31/10/23	1.32MB	Share
PTX	PTX results to be presented at world's largest blood meeting		17/10/23	1.16MB	Share
PTX	Notice of Annual General Meeting/Proxy Form		13/10/23	1.27MB	Share
PTX	Application for quotation of securities - PTX		31/08/23	24.99KB	Share
PTX	Section 708A Cleansing Notice		31/08/23	507.92KB	Share
PTX	Appendix 4G and Corporate Governance Statement		25/08/23	1.37MB	Share
PTX	Appendix 4E and 2023 Annual Report	PRICE SENSITIVE	25/08/23	1.24MB	Share
PTX	June 2023 Quarterly Update and Appendix 4C	PRICE SENSITIVE	27/07/23	6.49MB	Share
PTX	Application for quotation of securities - PTX		14/06/23	25.01KB	Share
PTX	Two PTX abstracts accepted at prestigious ISCT conference		16/05/23	897.76KB	Share
PTX	Initial Director's Interest Notice		15/05/23	243.47KB	Share
PTX	Notification regarding unquoted securities - PTX		15/05/23	27.54KB	Share
PTX	Experienced Pharma Executive Joins Prescient Board		15/05/23	1.16MB	Share
PTX	Notification of cessation of securities - PTX		05/05/23	22.3KB	Share
PTX	Change of Director's Interest Notices x3		02/05/23	430.43KB	Share
PTX	Application for quotation of securities - PTX		01/05/23	25.84KB	Share
PTX	Section 708A Cleansing Notice		01/05/23	483.08KB	Share
PTX	March 2023 Quarterly Update and Appendix 4C	PRICE SENSITIVE	28/04/23	1.53MB	Share
PTX	Change of Director's Interest Notices x2		04/04/23	417.73KB	Share
PTX	Application for quotation of securities - PTX		04/04/23	25.05KB	Share
PTX	Exercise and Expiry of Listed Options		04/04/23	942.19KB	Share
PTX	Continued promising results in PTX-100 TCL trial	PRICE SENSITIVE	16/03/23	2.08MB	Share
PTX	FDA grants broader orphan drug status to PTX100 for TCLs	PRICE SENSITIVE	09/03/23	893.45KB	Share
PTX	Revised Securities Trading Policy		27/02/23	1.08MB	Share
PTX	Appendix 4D and Half Year Financial Report	PRICE SENSITIVE	24/02/23	1.58MB	Share
PTX	Notification of Expiry of Listed Options		22/02/23	2.08MB	Share
PTX	Application for quotation of securities - PTX		09/02/23	24.98KB	Share
PTX	December 2022 Quarterly Update and Appendix 4C	PRICE SENSITIVE	25/01/23	1.19MB	Share
PTX	Application for quotation of securities - PTX		25/01/23	24.97KB	Share
PTX	Application for quotation of securities - PTX		05/01/23	24.97KB	Share
PTX	Change of Director's Interest Notice		14/12/22	268.38KB	Share
PTX	Notification of cessation of securities - PTX		14/12/22	23.25KB	Share
PTX	Section 708A Cleansing Notice		14/12/22	481.7KB	Share
PTX	Application for quotation of securities - PTX		14/12/22	26.42KB	Share
PTX	Application for quotation of securities - PTX		09/12/22	25.77KB	Share
PTX	Results of Annual General Meeting		29/11/22	898.94KB	Share
PTX	AGM Presentation	PRICE SENSITIVE	29/11/22	2.43MB	Share
PTX	Chair's Address to the 2022 Annual General Meeting		29/11/22	1.42MB	Share
PTX	Application for quotation of securities - PTX		15/11/22	25.77KB	Share
PTX	PTX Investor presentation and additional patient response		02/11/22	4.36MB	Share
PTX	September 2022 Quarterly Update and Appendix 4C	PRICE SENSITIVE	31/10/22	1.37MB	Share
PTX	Notice of Annual General Meeting/Proxy Form		27/10/22	775.92KB	Share
PTX	PTX-100 Trial Update	PRICE SENSITIVE	25/10/22	4.01MB	Share
PTX	Application for quotation of securities - PTX		17/10/22	25.6KB	Share
PTX	Section 708A Cleansing Notice		17/10/22	369.44KB	Share
PTX	Application for quotation of securities - PTX		13/10/22	25.77KB	Share
PTX	Change of Director's Interest Notices x2		12/10/22	322.53KB	Share
PTX	Application for quotation of securities - PTX		11/10/22	25.52KB	Share
PTX	Proposed issue of securities - PTX		11/10/22	25.27KB	Share
PTX	Placement Results	PRICE SENSITIVE	11/10/22	691.74KB	Share
PTX	SPP Results and Placement	PRICE SENSITIVE	07/10/22	883.36KB	Share
PTX	Trading Halt	PRICE SENSITIVE	07/10/22	861.26KB	Share
PTX	Extension of Share Purchase Plan		28/09/22	870.54KB	Share
PTX	CellPryme-A Investor Presentation		27/09/22	3.19MB	Share
PTX	PTX unveils CellPryme-A to boost CAR-T performance	PRICE SENSITIVE	23/09/22	1.8MB	Share
PTX	Prescient unveiling CellPryme-A at CAR-TCR summit in Boston		14/09/22	750.24KB	Share
PTX	Application for quotation of securities - PTX		09/09/22	25.77KB	Share
PTX	PTX strategic collaboration with MD Anderson Cancer Center	PRICE SENSITIVE	07/09/22	894.66KB	Share
PTX	Application for quotation of securities - PTX		01/09/22	25.77KB	Share
PTX	Proposed issue of securities - PTX		24/08/22	28.47KB	Share
PTX	Share Purchase Plan Booklet		24/08/22	597.65KB	Share
PTX	Prescient Therapeutics Launches Share Purchase Plan	PRICE SENSITIVE	24/08/22	831.85KB	Share
PTX	Share Purchase Plan Cleansing Notice		24/08/22	396.06KB	Share
PTX	PTX Presentation		23/08/22	2.62MB	Share
PTX	Appendix 4G and Corporate Governance Statement		23/08/22	1.55MB	Share
PTX	Appendix 4E and 2022 Annual Report	PRICE SENSITIVE	23/08/22	2.06MB	Share
PTX	PTX agreement with Thermo Fisher for scalable OmniCAR	PRICE SENSITIVE	18/08/22	695.52KB	Share
PTX	PTX OmniCAR cell manufacturing contract for clinical trials	PRICE SENSITIVE	16/08/22	673.53KB	Share
PTX	June 2022 Quarterly Update and Appendix 4C	PRICE SENSITIVE	25/07/22	1.24MB	Share
PTX	Application for quotation of securities - PTX		22/07/22	25.77KB	Share
PTX	US FDA Grants Orphan Drug Designation to PTX-100 for PTCL	PRICE SENSITIVE	15/07/22	299.4KB	Share
PTX	Key OmniCAR Patent Granted in US	PRICE SENSITIVE	05/07/22	525.88KB	Share
PTX	Application for quotation of securities - PTX		16/06/22	25.77KB	Share
PTX	PTX CellPryme-M presentation	PRICE SENSITIVE	08/06/22	7.35MB	Share
PTX	PTX unveils new clinic-ready CAR-T enhancement platform	PRICE SENSITIVE	08/06/22	1.19MB	Share
PTX	Application for quotation of securities - PTX		19/05/22	25.77KB	Share
PTX	PTX-200 AML expansion after another complete response	PRICE SENSITIVE	09/05/22	1.11MB	Share
PTX	PTX-200 AML expansion after another complete response		09/05/22	882.36KB	Share
PTX	Prescient to Present at AVID 2022 Meeting		03/05/22	2.94MB	Share
PTX	March 2022 Quarterly Update and Appendix 4C	PRICE SENSITIVE	29/04/22	706.28KB	Share
PTX	Notification of cessation of securities - PTX		14/04/22	22.62KB	Share
PTX	Application for quotation of securities - PTX		06/04/22	26.53KB	Share
PTX	Recruitment Open for Expansion Cohort of Phase 1B Study	PRICE SENSITIVE	05/04/22	1.04MB	Share
PTX	Investor Presentation		01/03/22	2.38MB	Share
PTX	Appendix 4D and Half Year Financial Report	PRICE SENSITIVE	25/02/22	447.78KB	Share
PTX	December 2021 Quarterly Update and Appendix 4C	PRICE SENSITIVE	31/01/22	426.4KB	Share
PTX	Application for quotation of securities - PTX		07/12/21	25KB	Share
PTX	Application for quotation of securities - PTX		30/11/21	30.37KB	Share
PTX	Section 708A Cleansing Statement		30/11/21	238.85KB	Share

PTX March 2024 Quarterly Update and Appendix 4C
30/04/24	PRICE SENSITIVE	392.22KB	Share
PTX PTX100 Ph1b results to be presented at specialist congress
08/04/24		253.17KB	Share
PTX Notification of cessation of securities - PTX
05/04/24		12.96KB	Share
PTX Appendix 4D and Half Year Financial Report
23/02/24	PRICE SENSITIVE	656.43KB	Share
PTX December 2023 Quarterly Update and Appendix 4C
31/01/24	PRICE SENSITIVE	2.53MB	Share
PTX PTX-100 Spotlight Presentation
18/12/23		1.35MB	Share
PTX PTX-100 Ph1b results show excellent safety & efficacy in TCL
11/12/23	PRICE SENSITIVE	1.3MB	Share
PTX Prescient Receives $2.4 Million R&D Tax Rebate
28/11/23		605.26KB	Share
PTX Results of Annual General Meeting
16/11/23		468.64KB	Share
PTX Chair and CEO AGM Presentation
16/11/23		15.43MB	Share
PTX PTX-100 abstract published online on ASH website
06/11/23		607.01KB	Share
PTX September 2023 Quarterly Update and Appendix 4C
31/10/23	PRICE SENSITIVE	1.32MB	Share
PTX PTX results to be presented at world's largest blood meeting
17/10/23		1.16MB	Share
PTX Notice of Annual General Meeting/Proxy Form
13/10/23		1.27MB	Share
PTX Application for quotation of securities - PTX
31/08/23		24.99KB	Share
PTX Section 708A Cleansing Notice
31/08/23		507.92KB	Share
PTX Appendix 4G and Corporate Governance Statement
25/08/23		1.37MB	Share
PTX Appendix 4E and 2023 Annual Report
25/08/23	PRICE SENSITIVE	1.24MB	Share
PTX June 2023 Quarterly Update and Appendix 4C
27/07/23	PRICE SENSITIVE	6.49MB	Share
PTX Application for quotation of securities - PTX
14/06/23		25.01KB	Share
PTX Two PTX abstracts accepted at prestigious ISCT conference
16/05/23		897.76KB	Share
PTX Initial Director's Interest Notice
15/05/23		243.47KB	Share
PTX Notification regarding unquoted securities - PTX
15/05/23		27.54KB	Share
PTX Experienced Pharma Executive Joins Prescient Board
15/05/23		1.16MB	Share
PTX Notification of cessation of securities - PTX
05/05/23		22.3KB	Share
PTX Change of Director's Interest Notices x3
02/05/23		430.43KB	Share
PTX Application for quotation of securities - PTX
01/05/23		25.84KB	Share
PTX Section 708A Cleansing Notice
01/05/23		483.08KB	Share
PTX March 2023 Quarterly Update and Appendix 4C
28/04/23	PRICE SENSITIVE	1.53MB	Share
PTX Change of Director's Interest Notices x2
04/04/23		417.73KB	Share
PTX Application for quotation of securities - PTX
04/04/23		25.05KB	Share
PTX Exercise and Expiry of Listed Options
04/04/23		942.19KB	Share
PTX Continued promising results in PTX-100 TCL trial
16/03/23	PRICE SENSITIVE	2.08MB	Share
PTX FDA grants broader orphan drug status to PTX100 for TCLs
09/03/23	PRICE SENSITIVE	893.45KB	Share
PTX Revised Securities Trading Policy
27/02/23		1.08MB	Share
PTX Appendix 4D and Half Year Financial Report
24/02/23	PRICE SENSITIVE	1.58MB	Share
PTX Notification of Expiry of Listed Options
22/02/23		2.08MB	Share
PTX Application for quotation of securities - PTX
09/02/23		24.98KB	Share
PTX December 2022 Quarterly Update and Appendix 4C
25/01/23	PRICE SENSITIVE	1.19MB	Share
PTX Application for quotation of securities - PTX
25/01/23		24.97KB	Share
PTX Application for quotation of securities - PTX
05/01/23		24.97KB	Share
PTX Change of Director's Interest Notice
14/12/22		268.38KB	Share
PTX Notification of cessation of securities - PTX
14/12/22		23.25KB	Share
PTX Section 708A Cleansing Notice
14/12/22		481.7KB	Share
PTX Application for quotation of securities - PTX
14/12/22		26.42KB	Share
PTX Application for quotation of securities - PTX
09/12/22		25.77KB	Share
PTX Results of Annual General Meeting
29/11/22		898.94KB	Share
PTX AGM Presentation
29/11/22	PRICE SENSITIVE	2.43MB	Share
PTX Chair's Address to the 2022 Annual General Meeting
29/11/22		1.42MB	Share
PTX Application for quotation of securities - PTX
15/11/22		25.77KB	Share
PTX PTX Investor presentation and additional patient response
02/11/22		4.36MB	Share
PTX September 2022 Quarterly Update and Appendix 4C
31/10/22	PRICE SENSITIVE	1.37MB	Share
PTX Notice of Annual General Meeting/Proxy Form
27/10/22		775.92KB	Share
PTX PTX-100 Trial Update
25/10/22	PRICE SENSITIVE	4.01MB	Share
PTX Application for quotation of securities - PTX
17/10/22		25.6KB	Share
PTX Section 708A Cleansing Notice
17/10/22		369.44KB	Share
PTX Application for quotation of securities - PTX
13/10/22		25.77KB	Share
PTX Change of Director's Interest Notices x2
12/10/22		322.53KB	Share
PTX Application for quotation of securities - PTX
11/10/22		25.52KB	Share
PTX Proposed issue of securities - PTX
11/10/22		25.27KB	Share
PTX Placement Results
11/10/22	PRICE SENSITIVE	691.74KB	Share
PTX SPP Results and Placement
07/10/22	PRICE SENSITIVE	883.36KB	Share
PTX Trading Halt
07/10/22	PRICE SENSITIVE	861.26KB	Share
PTX Extension of Share Purchase Plan
28/09/22		870.54KB	Share
PTX CellPryme-A Investor Presentation
27/09/22		3.19MB	Share
PTX PTX unveils CellPryme-A to boost CAR-T performance
23/09/22	PRICE SENSITIVE	1.8MB	Share
PTX Prescient unveiling CellPryme-A at CAR-TCR summit in Boston
14/09/22		750.24KB	Share
PTX Application for quotation of securities - PTX
09/09/22		25.77KB	Share
PTX PTX strategic collaboration with MD Anderson Cancer Center
07/09/22	PRICE SENSITIVE	894.66KB	Share
PTX Application for quotation of securities - PTX
01/09/22		25.77KB	Share
PTX Proposed issue of securities - PTX
24/08/22		28.47KB	Share
PTX Share Purchase Plan Booklet
24/08/22		597.65KB	Share
PTX Prescient Therapeutics Launches Share Purchase Plan
24/08/22	PRICE SENSITIVE	831.85KB	Share
PTX Share Purchase Plan Cleansing Notice
24/08/22		396.06KB	Share
PTX PTX Presentation
23/08/22		2.62MB	Share
PTX Appendix 4G and Corporate Governance Statement
23/08/22		1.55MB	Share
PTX Appendix 4E and 2022 Annual Report
23/08/22	PRICE SENSITIVE	2.06MB	Share
PTX PTX agreement with Thermo Fisher for scalable OmniCAR
18/08/22	PRICE SENSITIVE	695.52KB	Share
PTX PTX OmniCAR cell manufacturing contract for clinical trials
16/08/22	PRICE SENSITIVE	673.53KB	Share
PTX June 2022 Quarterly Update and Appendix 4C
25/07/22	PRICE SENSITIVE	1.24MB	Share
PTX Application for quotation of securities - PTX
22/07/22		25.77KB	Share
PTX US FDA Grants Orphan Drug Designation to PTX-100 for PTCL
15/07/22	PRICE SENSITIVE	299.4KB	Share
PTX Key OmniCAR Patent Granted in US
05/07/22	PRICE SENSITIVE	525.88KB	Share
PTX Application for quotation of securities - PTX
16/06/22		25.77KB	Share
PTX PTX CellPryme-M presentation
08/06/22	PRICE SENSITIVE	7.35MB	Share
PTX PTX unveils new clinic-ready CAR-T enhancement platform
08/06/22	PRICE SENSITIVE	1.19MB	Share
PTX Application for quotation of securities - PTX
19/05/22		25.77KB	Share
PTX PTX-200 AML expansion after another complete response
09/05/22	PRICE SENSITIVE	1.11MB	Share
PTX PTX-200 AML expansion after another complete response
09/05/22		882.36KB	Share
PTX Prescient to Present at AVID 2022 Meeting
03/05/22		2.94MB	Share
PTX March 2022 Quarterly Update and Appendix 4C
29/04/22	PRICE SENSITIVE	706.28KB	Share
PTX Notification of cessation of securities - PTX
14/04/22		22.62KB	Share
PTX Application for quotation of securities - PTX
06/04/22		26.53KB	Share
PTX Recruitment Open for Expansion Cohort of Phase 1B Study
05/04/22	PRICE SENSITIVE	1.04MB	Share
PTX Investor Presentation
01/03/22		2.38MB	Share
PTX Appendix 4D and Half Year Financial Report
25/02/22	PRICE SENSITIVE	447.78KB	Share
PTX December 2021 Quarterly Update and Appendix 4C
31/01/22	PRICE SENSITIVE	426.4KB	Share
PTX Application for quotation of securities - PTX
07/12/21		25KB	Share
PTX Application for quotation of securities - PTX
30/11/21		30.37KB	Share
PTX Section 708A Cleansing Statement
30/11/21		238.85KB	Share

REFRESH

1 2 3 4

(20min delay)
Last 5.0¢		Change -0.002(3.85%)		Mkt cap ! $40.26M

Open	High	Low	Value	Volume
5.2¢	5.2¢	4.9¢	$21.91K	440.0K

Buyers (Bids)

No.	Vol.	Price($)
7	189208	4.9¢

Sellers (Offers)

Price($)	Vol.	No.
5.0¢	6566	1

View Market Depth

No.	Vol.	Price($)
7	189208	0.049
6	246249	0.048
3	95000	0.047
4	286759	0.046
4	1088000	0.045

Price($)	Vol.	No.
0.050	6566	1
0.051	12000	1
0.052	115063	2
0.053	50000	1
0.054	60000	1

Last trade - 15.43pm 01/05/2024 (20 minute delay)


Last 5.0¢		Change -0.002 ( 0.00 %)
Open	High	Low	Volume
5.0¢	5.0¢	4.9¢	73482
Last updated 15.59pm 01/05/2024 ?

PTX (ASX) Chart

PRESCIENT THERAPEUTICS LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories